Aegle Therapeutics’ Post

Roche used the Changing Picture design to visually depict distinct patient profiles related to Chronic Lymphocytic Leukemia (CLL). When you turn each page, the featured image automatically morphs into a representation of the highlighted patient type. This piece was used to educate physicians on the different management plans of CLL. See more of our Pharma work here: https://lnkd.in/gH_ifGe3 #patientcompliance #physicianeducation #CME #continuingmedicaleducation #pharmaceuticalsolutions #print #printadvertising #salesaid #pharmaaids

A new paper is online - prepared in collaboration with Sqilline. Enjoy reading! Manova M, Arabadjiev J, Mangaldzhiev R, et al. → Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice. Biotechnology & Biotechnological Equipment 2023;37(1); https://lnkd.in/deb_m-JM

Rules-Based Medicine a Q² Solutions Company has added pTau217 to its menu of neurodegenerative biomarkers by ultrasensitive single molecule array (Simoa) technology. A recent study found that a pTau217 immunoassay identified abnormal amyloid β (Aβ) and tau in correlation to cerebrospinal fluid biomarkers and PET scans.[1] If your pipeline includes therapeutics for Alzheimer’s or other neurodegenerative disorders, reach out to RBM for pTau217 and other ultrasensitive CNS assays: https://bit.ly/3whf3yz 1. Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. 2024;81(3):255–263. doi:10.1001/jamaneurol.2023.5319.

On World Cancer Day, we are all reminded of the bravery of our most critical patients and how crucial it is to provide the best healthcare possible for patients everywhere. At Sysmex, we are dedicated to developing innovative analyzers to help clinical labs provide accurate results regardless of the diagnosis. White Precursor Cell (WPC) testing on the XN-20™ hematology module offers automated, next-level analysis of white blood cells, giving highly skilled laboratory scientists sensitive and specific flagging for the crucial identification of abnormal cells. Efficiency can be gained when WPC testing is reflexed using the XN analyzer’s onboard rules or Caresphere™ Workflow Solution (WS). For more information on how Sysmex can help your laboratory help provide diagnostic testing for critical patients, contact your Sysmex Sales Representative or visit https://ow.ly/nYb450QxtNh. *XN analyzers are FDA-cleared to classify and count blood cells. #WorldCancerDay #Sysmex #Hematology #TogetherForABetterHealthcareJourney

Calling all #lupus specialists & researchers: The April edition of our Literature Highlights & detailed slide decks are now available on the Lupus-Forum, featuring key advancements in lupus research and therapeutics. This month, we delve into topics such as the safety and efficacy of CD19 #CAR-T cell therapy, the role of #anifrolumab in treating #SLE, the establishment of autoantigen-specific Treg-cell-based therapy in #LN, and the latest on cardiovascular risk factors in #SLE patients: https://lnkd.in/dCk9aBNk

Safety, Efficacy and Cellular Kinetics of YTB323, a Rapid Manufacturing CAR-T Cell Therapy Targeting CD19 on B Cells, for Severe Refractory Systemic Lupus Erythematosus Preliminary data from this clinical trial including the first three sentinel patients suggest favorable safety, CAR-T cell expansion, B cell depletion and initial efficacy, supporting continuation of the study to evaluate YTB323 in srSLE.

#Webinar now available on demand! Advancing clinical-grade tumor-infiltrating #lymphocyte therapy manufacturing Featuring Miltenyi Biotec’s Arina Riabinska (R&D Team Coordinator, Personalized Immunotherapy) who will discuss how to generate tumor-reactive #Tcells (TRTs) for TIL therapy, all within a standardized and seamlessly automated framework. Watch the webinar to gain insight on: • How to master closed system automation for the efficient production of TIL cell products • Solving clinical-scale TIL manufacturing challenges • GMP-compliant cell sorting for specific tumor-reactive T cell subsets in a closed system

Biotech communications professionals often use terms like paradigm shifting, best-in-class, novel, etc. I’m guilty of it too. But the topline results presented today are more than just a subjective interpretation of data. Despite a relatively small study, the MG patients that responded to Descartes-08 did so with disease modifying results. This treatment didn’t just manage their symptoms – it altered how they were able to live.   Proud to be part of Cartesian Therapeutics, looking forward to advancing Descartes-08 for #myastheniagravis to a phase 3 trial, and seeing the future potential of our platform for #autoimmunity.